1-Methoxy-1-methyl-cyclobutan | 42984-37-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-Methoxy-1-methyl-cyclobutan
• 英文别名: 1-Methyl-1-methoxycyclobutan；1-Methoxy-1-methylcyclobutane
• CAS: 42984-37-2
• 化学式: C₆H₁₂O
• 分子量: 100.161
• InChiKey: DXIDBOGURSGGDZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  (1-methylcyclopropyl)methyl tosylate 在 /BRN= 1098229/ 作用下， 生成 1-Methoxy-1-methyl-cyclobutan
  参考文献：
  名称：

  Cyclopropylcarbinyl p-Toluenesulfonate Solvolysis. II.¹ 1-Methyl-Substituent Effect

  摘要：

  DOI：

  10.1021/jo01344a524

文献信息

• [EN] SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS<br/>[FR] QUINAZOLINES SUBSTITUÉES PAR SULFOXIMINE POUR COMPOSITIONS PHARMACEUTIQUES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014072244A1

  公开（公告）日：2014-05-15

  This invention relates to novel sulfoximine substituted quinazoline derivatives of formula (I), wherein Ar, R1 and R2 are as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.

  这项发明涉及一种新型的配方(I)的磺酰胺取代喹唑啉衍生物，其中Ar、R1和R2如描述和声明中所定义，并且它们作为MNK1（MNK1a或MNK1b）和/或MNK2（MNK2a或MNK2b）激酶抑制剂的用途，含有这些化合物的药物组合物，以及将其用作治疗或改善MNK1（MNK1a或MNK1b）和/或MNK2（MNK2a或MNK2b）介导的疾病的药剂的方法。
• [EN] PYRAZOLYL SUBSTITUTED TETRAHYDROPYRANYLSULFONES<br/>[FR] TÉTRAHYDROPYRANYLSULFONES À SUBSTITUTION PYRAZOLYLE
  申请人：GRUENENTHAL GMBH

  公开号：WO2017059966A1

  公开（公告）日：2017-04-13

  The invention relates to pyrazolyl substituted tetrahydropyranylsulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

  这项发明涉及吡唑基取代的四氢吡喃基磺酮作为电压门控钙通道阻滞剂，以及含有这些化合物的药物组合物，还涉及这些化合物用于治疗和/或预防疼痛以及其他疾病和/或紊乱。
• PYRAZOLYL SUBSTITUTED TETRAHYDROPYRANYLSULFONES
  申请人：GRÜNENTHAL GMBH

  公开号：US20170101397A1

  公开（公告）日：2017-04-13

  The invention relates to pyrazolyl substituted tetrahydropyranylsulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

  这项发明涉及吡唑基取代的四氢吡喃基磺酮作为电压门控钙通道阻滞剂，以及含有这些化合物的药物组合物，还涉及这些化合物用于治疗和/或预防疼痛以及其他疾病和/或紊乱。
• [EN] CHINAZOLINE DERIVATIVES AS AURORA KINASE INHIBITORS<br/>[FR] DERIVES DE QUINAZOLINE TENANT LIEU D'INHIBITEURS DE L'AURORA KINASE
  申请人：ASTRAZENECA AB

  公开号：WO2004113324A1

  公开（公告）日：2004-12-29

  Quinazoline derivatives of formula (I) (A chemical formula should be inserted here - please see paper copy enclosed herewith) formula (I) for use in the treatment of proliferative diseases such as cancer and in the preparation of medicaments for use in the treatment of proliferative diseases, and to processes for their preparation, as well as pharmaceutical compositions containing them as active ingredient.

  化学式（I）的喹唑啉衍生物用于治疗增生性疾病，如癌症，并用于制备用于治疗增生性疾病的药物，以及用于其制备的方法，以及含有它们作为活性成分的药物组合物。
• Chinazoline derivatives as aurora kinase inhibitors
  申请人：Mortlock Austen Andrew

  公开号：US20060178382A1

  公开（公告）日：2006-08-10

  Quinazoline derivatives of formula (I) (A chemical formula should be inserted here—please see paper copy enclosed herewith) formula (I) for use in the treatment of proliferative diseases such as cancer and in the preparation of medicaments for use in the treatment of proliferative diseases, and to processes for their preparation, as well as pharmaceutical compositions containing them as active ingredient.

  公式（I）的喹唑啉衍生物（化学式应在此处插入-请参见随附的纸质副本）公式（I）用于治疗增生性疾病，如癌症，并用于制备用于治疗增生性疾病的药物，以及用于它们的制备过程，以及含有它们作为活性成分的制药组合物。